Translational potential of a novel osteoclast inhibitor, eliglustat, in myeloma bone disease
<p>Multiple myeloma is a fatal haematological malignancy, in which the majority of patients either present with or develop a destructive and debilitating osteolytic bone disease. The bone disease is characterised by an increase in osteoclastogenesis and by osteoblast suppression. Current trea...
Yazar: | Leng, H |
---|---|
Diğer Yazarlar: | Simon, K |
Materyal Türü: | Tez |
Dil: | English |
Baskı/Yayın Bilgisi: |
2019
|
Konular: |
Benzer Materyaller
-
Interleukin-32 promotes osteoclast differentiation but not osteoclast activation
Yazar:: Mabilleau, G, ve diğerleri
Baskı/Yayın Bilgisi: (2009) -
Stimulation of osteoclast formation by inflammatory synovial fluid
Yazar:: Adamopoulos, I, ve diğerleri
Baskı/Yayın Bilgisi: (2006) -
Increased osteoclastic activity in acute Charcot's osteoarthropathy: the role of receptor activator of nuclear factor-kappaB ligand
Yazar:: Mabilleau, G, ve diğerleri
Baskı/Yayın Bilgisi: (2008) -
Expression of Receptor Activator of Nuclear – Kappa β Ligand in Patients with Metastatic Bone Disease
Yazar:: Magetsari, Rahadyan, ve diğerleri
Baskı/Yayın Bilgisi: (2022) -
Maintenance therapy in multiple myeloma
Yazar:: Jean-Luc Harousseau
Baskı/Yayın Bilgisi: (2009-08-01)